article Open AccessTop 1% cited
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
Clinical Cancer Research · 2010 · Vol. 16(21) · pp. 5222–5232
Torsten O. Nielsen✉(Vancouver Coastal Health Research Institute)Joel S. Parker(Washington University in St. Louis)Samuel Leung(University of Utah)D. Voduc(Vancouver Coastal Health Research Institute)Mark Ebbert(Vancouver Coastal Health Research Institute)Tammi L. Vickery(Vancouver Coastal Health Research Institute)Sherri R. Davies(University of British Columbia)Jacqueline Snider(Vancouver Coastal Health Research Institute)Inge J. Stijleman(Washington University in St. Louis)Jerry P. Reed(Vancouver Coastal Health Research Institute)Maggie C.U. Cheang(University of North Carolina at Chapel Hill)Elaine R. Mardis(University of North Carolina at Chapel Hill)Charles M. Perou(University of Utah)Philip S. Bernard(University of British Columbia)Matthew J. Ellis(University of North Carolina at Chapel Hill)
Abstract
The PAM50 gene expression test for intrinsic biological subtype can be applied to large series of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than clinical factors and IHC using standard cut points.
Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchEstrogen and related hormone effectsBreast cancerOncologyImmunohistochemistryInternal medicineMedicineEstrogen receptorHazard ratioProgesterone receptorTamoxifenProportional hazards model
MeSH terms
AdultAgedAged, 80 and overBreast NeoplasmsCarcinomaDiagnostic Techniques, EndocrineFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingPrognosisReceptors, EstrogenTamoxifenAntineoplastic Agents, Hormonal
Funding
- BC Cancer Agency
Citations
818
FWCI
17.08
field-weighted impact
References
39
Percentile
99%
vs. same field & year
Citations per year
Cited by
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Annals of Oncology · 2013 · 3,672 citations
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
BMC Cancer · 2014 · 304 citations
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Annals of Oncology · 2015 · 1,820 citations
References
The molecular portraits of breast tumors are conserved across microarray platforms
BMC Genomics · 2006 · 1,463 citations
Proportional hazards tests and diagnostics based on weighted residuals
Biometrika · 1994 · 5,490 citations
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
JNCI Journal of the National Cancer Institute · 2005 · 2,064 citations
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Clinical Cancer Research · 2008 · 1,187 citations
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
New England Journal of Medicine · 2004 · 6,318 citations
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
The Lancet Oncology · 2009 · 1,391 citations
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
JNCI Journal of the National Cancer Institute · 2006 · 2,125 citations
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
JNCI Journal of the National Cancer Institute · 2009 · 2,199 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.